Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from Wayne State University update current data on cancer vaccines
December 24th, 2008
According to recent research from the United States, "5'-N-Phenylacetyl sTn (sTnNPhAc), an unnatural derivative of sTn antigen expressed by many tumors, and its alpha-linked protein conjugates were prepared and investigated to explore glycoconjugate cancer vaccines. sTnNPhAc alpha-KLH elicited a robust T cell dependent immunity." "The antiserum derived from sTnNPhAc alpha or sTnNPhAc beta-KLH-inoculated mice was similarly reactive to sTnNPhAc alpha and sTnNPhAc but showed very little reactivity to sTn, NeuNPhAc alpha(2,3)GalNAc-a regioisomer of sTnNPhAc, isolated phenylacetyl group, and the linker employed to conjugate sTnNPhAc and carrier protein. It was concluded that...
Source: Vaccine Weekly (2008-12-24)
|
